10178- ACT-11 A PHASE 1 STUDY OF LOMUSTINE MONOTHERAPY AND COMBINATION THERAPY WITH PROCARBAZINE, LOMUSTINE, AND VINCRISTINE IN JAPANESE PATIENTS WITH GLIOMA (LOMG) Authors: Yoshiki Arakawa, Yasuhide Makino, Etsuko Yamamoto, Yasuhide Takeuchi, Shigeki Takada, Noritaka Sano, Masahiro Tanji, Yohei Mineharu, Atsushi Yonezawa Published: 2024 ABSTRACT AbstractIn the development of treatments for glioma, international clinical trials have demonstrated the efficacy of carmustine (BCNU), lomustine (CCNU), and methyl-CCNU against glioma. In Japan, nimustine (ACNU) has been developed and is used as a treatment for glioma. Internationally, compared to BCNU, the combination therapy of procarbazine, lomustine (CCNU), and vincristine (PCV therapy) has been confirmed to extend the survival period for glioma Grade 2/3, and numerous clinical trial results using PCV therapy have been accumulated. As a result, PCV therapy has become the standard treatment for Grade 2/3 oligodendroglioma and Grade 2 astrocytoma worldwide. However, lomustine is not approved in Japan, making it impossible to implement the standard treatment used overseas. Therefore, in 2019, the Japan Society for Neuro-Oncology submitted a request for the domestic development of lomustine to the ‘Meeting for the Evaluation of Unapproved Drugs and Indications with High Medical Needs.’ As a result of deliberation, it was determined in 2022 that clinical trial results involving Japanese subjects were necessary. Consequently, this physician-led trial was planned as a Phase I trial of lomustine, and the trial began in 2023. This report provides an overview and background of this clinical trial.